Evolving Treatment Paradigms in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Managed Care Considerations on Immunoglobulin Replacement Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live webinars held on October 10th and October 12th 2018. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 29, 2018 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
CSL Behring

Effective and timely treatment of primary immunodeficiency diseases can greatly improve the quality of life and outcomes in CIDP patients. With the advancement and complexity of different treatment options, including immunoglobulin replacement therapies that have become available recently in different administration methods, it is critical that medical directors, payers, practicing physicians, nurse case managers and other HCPs are educated on the role of immunoglobulin replacement therapy and understand all of the safety and efficacy data to make appropriate formulary and clinical decisions. Recent surveys, research and evaluations from our activities have shown that these healthcare professionals need updates on these novel options, and how they can integrate them into the treatment paradigm and optimize costs. This webcast activity will feature strategies to overcome challenges in the optimal treatment of CIPD, updates on immunoglobulin replacement therapies, and practical managed care approaches to provide cost-effective solutions to improve both clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Identify the clinical and electrophysiological signs and symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP)

  • Examine the safety and efficacy of currently available and emerging immunoglobulin (Ig) replacement therapies for the management of CIDP and apply them to patient cases using evidence-based medicine

  • Employ shared decision-making when choosing treatment for patients with CIDP in the initial management and maintenance settings

  • Analyze novel administration methods for immunoglobulin (Ig) replacement therapies and how they are changing the treatment paradigm

  • Examine the total cost of care for CIDP, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs

  • Apply methods to enable optimal cost management of Ig replacement therapies to be realized by multiple CIPD stakeholders including managed care organizations

Faculty: Gary Owens, MD
Gary Owens Associates


Gary Owens, MD has no relevant financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue